Myocardial Ischemia and Ventricular Tachycardia on Continuous Electrocardiographic Monitoring and Risk of Cardiovascular Outcomes After Non-ST-Segment Elevation Acute Coronary Syndrome (from the MERLIN-TIMI 36 Trial)

被引:13
|
作者
Harkness, James R. [1 ,2 ]
Morrow, David A. [1 ,3 ,4 ]
Braunwald, Eugene [1 ,3 ,4 ]
Ren, Fang [1 ,3 ,4 ]
Lopez-Sendon, J. [5 ]
Bode, Christopher [6 ]
Budaj, Andrzej [7 ]
Scirica, Benjamin M. [1 ,3 ,4 ]
机构
[1] TIMI Study Grp, Boston, MA USA
[2] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[3] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Boston, MA USA
[5] Hosp Univ La Paz, Madrid, Spain
[6] Med Univ Klin, Freiburg, Germany
[7] Grochowski Hosp, Postgrad Med Sch, Warsaw, Poland
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2011年 / 108卷 / 10期
关键词
SYNDROME-THROMBOLYSIS; METABOLIC EFFICIENCY; LESS ISCHEMIA; INFARCTION; RANOLAZINE; DEFIBRILLATOR; PREVALENCE; EVENTS; MARKER;
D O I
10.1016/j.amjcard.2011.06.058
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Among patients with non-ST-segment elevation acute coronary syndromes, recurrent ischemia and ventricular arrhythmias detected on continuous electrocardiographic monitoring remain common events that are associated with worse outcomes. The relative clinical significance of both events together is not well described. We determined the risk associated with ischemia (>= 1 mm ST depression lasting >= 1 minutes) and ventricular tachycardia (VT) (>= 4 beats) detected on 7-day continuous electrocardiographic monitoring in 6,355 patients with non-ST-segment elevation acute coronary syndromes from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation Acute Coronary Syndrome Thrombolysis In Myocardial Infarction (MERLIN-TIMI) 36 trial. The patients were categorized into 4 groups according to the presence or absence of VT and ischemia. Cardiovascular death, sudden cardiac death (SCD), myocardial infarction, and recurrent ischemia were assessed during a median follow-up of 348 days. A total of 60.0% patients had no VT or ischemia, 20.0% had VT alone, 14.7% had ischemia alone, and 5.3% had both. The patients with either VT or ischemia were at increased risk of cardiovascular outcomes. The combination of ischemia and VT identified a particularly high-risk population for cardiovascular death (10.1% vs 3.0%, p <0.001), SCD (7.8% vs 0.9%, p <0.001), and myocardial infarction (15.4% vs 6.2%, p <0.001) compared to patients with neither. The addition of arrhythmia and ischemia significantly improved the clinical model for predicting cardiovascular death or SCD (p <0.001). In patients with both ischemia and VT, 66.6% of SCD occurred within 90 days of the non-ST-segment elevation acute coronary syndromes. In conclusion, in >6,300 patients with non-ST-segment elevation acute coronary syndromes, the presence of myocardial ischemia or VT alone, and particularly in combination, was independently associated with poor cardiovascular outcomes and thus provides incremental improvement in early risk stratification. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;108:1373-1381)
引用
收藏
页码:1373 / 1381
页数:9
相关论文
共 50 条
  • [21] Letter by Ayalloore and LeLorier Regarding Article, "Relationship Between Nonsustained Ventricular Tachycardia After Non-ST-Elevation Acute Coronary Syndrome and Sudden Cardiac Death: Observations From the Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial"
    Ayalloore, Siby G.
    LeLorier, Paul
    CIRCULATION, 2011, 123 (14) : E404 - E404
  • [22] Ranolazine reduces ischemia as detected on continuous ECG (Holter) in patients with non-ST-elevation ACS in the MERLIN-TIMI 36 trial
    Scirica, Benjamin
    Hedgepeth, Chester M., III
    Bode, Christophe
    Dalby, Anthony
    Murphy, Sabina A.
    Revin, Vyacheslav M.
    Shimmer, Margarita
    Karwatowska-Prokopczuk, Ewa
    Stone, Peter
    Morrow, David A.
    CIRCULATION, 2007, 116 (16) : 383 - 383
  • [23] ASSOCIATION OF ELECTROCARDIOGRAPHIC MARKERS WITH HEART FAILURE FOLLOWING NON-STELEVATION ACUTE CORONARY SYNDROME: RESULTS FROM THE MERLIN-TIMI 36 TRIAL
    Syed, Zeeshan
    Ali, Moiz
    Scirica, Benjamin
    Morrow, David
    Stultz, Collin
    Guttag, John
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E419 - E419
  • [24] T-WAVE ALTERNANS (TWA) IS ASSOCIATED WITH CARDIOVASCULAR MORTALITY AND NSVT IN THE MERLIN-TIMI 36 TRIAL OF RANOLAZINE VERSUS PLACEBO IN PATIENTS WITH NON-ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME
    Scirica, Benjamin
    Nieminen, Tuomo
    Pegler, Jose R. M.
    Tavares, Caio
    Pagotto, Vitor P. F.
    Kanas, Alexandre F.
    Sobrado, Marcel F.
    Nearing, Bruce
    Cho, Ji
    Morrow, David
    Belardinelli, Luiz
    Verrier, Richard
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (10) : E257 - E257
  • [25] Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of Arrhythmias in patients with Non-ST-Segment-Elevation acute coronary syndrome - Thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) Randomized controlled trial
    Scirica, Benjamin M.
    Morrow, David A.
    Hod, Hanoch
    Murphy, Sabina A.
    Belardinelli, Luiz
    Hedgepeth, Chester M.
    Molhoek, Peter
    Verheugt, Freek W. A.
    Gersh, Bernard J.
    McCabe, Carolyn H.
    Braunwald, Eugene
    CIRCULATION, 2007, 116 (15) : 1647 - 1652
  • [26] Efficacy of Ranolazine in Patients With Chronic Angina Observations From the Randomized, Double-Blind, Placebo-Controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial
    Wilson, Sean R.
    Scirica, Benjamin M.
    Braunwald, Eugene
    Murphy, Sabina A.
    Karwatowska-Prokopczuk, Ewa
    Buros, Jacqueline L.
    Chaitman, Bernard R.
    Morrow, David A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (17) : 1510 - 1516
  • [27] Impact of angina frequency on medical resource utilization and cost after non-ST elevation acute coronary syndromes: Insights from the MERLIN-TIMI 36 randomized trial
    Lei, Yang
    Arnold, Suzanne V.
    Morrow, David A.
    Chan, Paul
    Mahoney, Elizabeth M.
    Wang, Kaijun
    Robertus, Katherine
    Case, Rebekah
    Kempf, Judith A.
    Cohen, David J.
    CIRCULATION, 2008, 117 (21) : E467 - E467
  • [28] Osteoprotegerin and the Risk of Recurrent Events in Patients With Non-ST elevation Acute Coronary Syndromes (NSTE-ACS): Observations From MERLIN-TIMI 36
    Bonaca, Marc
    Omland, Torbjorn
    Sabatine, Marc S.
    Murphy, Sabina A.
    Scirica, Benjamin M.
    Rasmussen, Lars M.
    Flyvbjerg, Allan
    Morrow, David A.
    CIRCULATION, 2009, 120 (18) : S1034 - S1034
  • [29] Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36
    Bonaca, Marc P.
    O'Malley, Ryan G.
    Murphy, Sabina A.
    Jarolim, Petr
    Conrad, Michael J.
    Braunwald, Eugene
    Sabatine, Marc S.
    Morrow, David A.
    EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE, 2015, 4 (05) : 431 - 440
  • [30] Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36
    Zelniker, Thomas A.
    Morrow, David A.
    Scirica, Benjamin M.
    Furtado, Jeremy D.
    Guo, Jianping
    Mozaffarian, Dariush
    Sabatine, Marc S.
    O'Donoghue, Michelle L.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (08):